Chen, Ming-Huang

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology

Drug Transport and Resistance MechanismsPharmacogenetics and Drug Metabolism

Cited by 144

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H. (2020) · Cancers

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 105

Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis

Chang, Y.-C., Su, C.-Y., Chen, M.-H., Chen, W.-S., Chen, C.-L., & Hsiao, M. (2017) · Molecular Cancer

Cellular transport and secretionMechanisms of cancer metastasis

Cited by 74

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Liu, C.-Y., Huang, T.-T., Chu, P.-Y., Huang, C.-T., Lee, C.-H., Wang, W.-L., Lau, K.-Y., Tsai, W.-C., Chao, T.-I., Su, J.-C., et al. (2017) · Experimental & Molecular Medicine

Protein Tyrosine PhosphatasesCytokine Signaling Pathways and Interactions

Cited by 40